FindMyKOL

Michael Via

Basic profile

Mount Sinai Beth Israel

ORCIDNone on fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionNew York, NY · NortheastSpecialtyEndocrinology, Diabetes & MetabolismFocusEndocrinology/Metabolic
Active KOLFindMyKOL type: RegionalLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Michael Via is an Endocrinology/Metabolic physician affiliated with Mount Sinai Beth Israel. OpenAlex indexes 58 publications with 992 citations (h-index 13).

Overview

Scholarship

indexed output and impact (OpenAlex)
58publications

Publications indexed by OpenAlex. Counts exclude supporting files.

992citations

Citations across these publications.

13h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
4companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Industry payments

4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • Madrigal Pharmaceuticals
    Program year20253 payments
    $1,682
  • Novo Nordisk Inc
    Program year20252 payments
    $1,628
  • Chiesi USA, Inc.
    Program year20252 payments
    $625
All 4 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Metabolism & gastrointestinal

    57.3%
    Insulin Analog15.9%
    Novolog Flexpen23%Basaglar Kwikpen U-10019%Tresiba Flextouch U-20016%Humalog Kwikpen U-10013%Lantus Solostar9%Levemir Flextouch6%Levemir Flexpen5%Insulin Lispro Kwikpen U-1004%Novolog3%Tresiba Flextouch U-1003%
    Part D<11 patients
    Biguanide (metformin)10.3%
    Metformin Hcl72%Metformin Hcl Er28%
    Part D≥61 patients

    + 8 more classes in this area

  • Hormonal (systemic)

    22.3%
    l-Thyroxine17.7%
    Levothyroxine Sodium76%Synthroid24%
    Part D≥98 patients
    Calcium-sensing Receptor Agonist1.7%
    Cinacalcet Hcl100%
    Part D<11 patients

    + 3 more classes in this area

  • Cardiovascular

    17.9%
    Statin7.5%
    Atorvastatin Calcium65%Rosuvastatin Calcium35%
    Part D≥35 patients
    Angiotensin receptor blocker (ARB)3.6%
    Losartan Potassium88%Valsartan12%
    Part D<11 patients

    + 7 more classes in this area

Where care is delivered (Part B)16% facility · 84% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”